Published in:
19-10-2022 | COVID-19 Vaccination | Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)
SARS-CoV-2 Infection and Vaccination Cutaneous Manifestations for the Inpatient Dermatologist
Authors:
Sonia Himed, Ashley Gray, Zaynah Awethe, Karissa Libson, Benjamin H. Kaffenberger, Abraham M. Korman, John C. L. Trinidad
Published in:
Current Dermatology Reports
|
Issue 4/2022
Login to get access
Abstract
Purpose of Review
The overall purpose of this review was to characterize and summarize cutaneous eruptions associated with coronavirus disease 2019 (COVID-19) as well as COVID-19 vaccination.
Recent Findings
Cutaneous eruptions associated with COVID-19 infection have a reported frequency of 1–20%. Increased COVID-19 disease severity has been associated with morbilliform exanthems, urticaria, retiform purpura, and livedo racemosa. Papulovesicular eruptions were associated with a milder COVID-19 disease course. A range of dermatoses have also been reported with COVID-19 vaccination but have rarely prevented subsequent vaccination.
Summary
Dermatologists should be aware of the associations between COVID-19 disease severity and cutaneous eruptions. Livedo racemosa and retiform purpura are particularly associated with increased disease severity and death. In the setting of COVID-19 vaccination, cutaneous eruptions can largely be managed symptomatically and very rarely do these reactions prevent subsequent vaccination.